Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
N-acetylcys..
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
Summary
All studies
Mortality
Hospitalization
Serious outcomes
RCTs
RCT mortality
All outcomes

Feedback
Home   COVID-19 treatment studies for Paxlovid  COVID-19 treatment studies for Paxlovid  C19 studies: Paxlovid  Paxlovid   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Povidone-Iod.. (meta)
Conv. Plasma (meta) Probiotics (meta)
Curcumin (meta) Proxalutamide (meta)
Ensovibep (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychlor.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Outcomes in COVID-19 paxlovid studies
Outcomes in paxlovid studies. PAXLOVID™ is an investigational SARS-CoV-2 protease inhibitor antiviral therapy combining PF-07321332 and ritonavir.
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ All studies 83% 2 2,939 Improvement, Studies, Patients Relative Risk Mortality 96% 1 2,085 Hospitalization 84% 2 2,939 RCTs 83% 2 2,939 Early 83% 2 2,939 Paxlovid for COVID-19 c19early.com/pl Jan 17, 2022 Favors paxlovid Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pfizer (DB RCT) 96% 0.04 [0.00-0.68] death 0/1,039 12/1,046 Improvement, RR [CI] Treatment Control Pfizer (DB RCT) 70% 0.30 [0.08-1.08] hosp. 3/428 10/426 Tau​2 = 0.76, I​2 = 37.8%, p = 0.049 Early treatment 83% 0.17 [0.03-0.99] 3/1,467 22/1,472 83% improvement All studies 83% 0.17 [0.03-0.99] 3/1,467 22/1,472 83% improvement 2 paxlovid COVID-19 studies c19early.com/pl Jan 17, 2022 Tau​2 = 0.76, I​2 = 37.8%, p = 0.049 Effect extraction pre-specified Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pfizer (DB RCT) 96% 0.04 [0.00-0.68] 0/1,039 12/1,046 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.025 Early treatment 96% 0.04 [0.00-0.68] 0/1,039 12/1,046 96% improvement All studies 96% 0.04 [0.00-0.68] 0/1,039 12/1,046 96% improvement 1 paxlovid COVID-19 mortality result c19early.com/pl Jan 17, 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.025 Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pfizer (DB RCT) 88% 0.12 [0.06-0.25] hosp. 8/1,039 66/1,046 Improvement, RR [CI] Treatment Control Pfizer (DB RCT) 70% 0.30 [0.08-1.08] hosp. 3/428 10/426 Tau​2 = 0.12, I​2 = 29.2%, p < 0.0001 Early treatment 84% 0.16 [0.07-0.37] 11/1,467 76/1,472 84% improvement All studies 84% 0.16 [0.07-0.37] 11/1,467 76/1,472 84% improvement 2 paxlovid COVID-19 hospitalization results c19early.com/pl Jan 17, 2022 Tau​2 = 0.12, I​2 = 29.2%, p < 0.0001 Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pfizer (DB RCT) 96% 0.04 [0.00-0.68] death 0/1,039 12/1,046 Improvement, RR [CI] Treatment Control Pfizer (DB RCT) 70% 0.30 [0.08-1.08] hosp. 3/428 10/426 Tau​2 = 0.76, I​2 = 37.8%, p = 0.049 Early treatment 83% 0.17 [0.03-0.99] 3/1,467 22/1,472 83% improvement All studies 83% 0.17 [0.03-0.99] 3/1,467 22/1,472 83% improvement 2 paxlovid COVID-19 serious outcomes c19early.com/pl Jan 17, 2022 Tau​2 = 0.76, I​2 = 37.8%, p = 0.049 Effect extraction pre-specified Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pfizer (DB RCT) 96% 0.04 [0.00-0.68] death 0/1,039 12/1,046 Improvement, RR [CI] Treatment Control Pfizer (DB RCT) 70% 0.30 [0.08-1.08] hosp. 3/428 10/426 Tau​2 = 0.76, I​2 = 37.8%, p = 0.049 Early treatment 83% 0.17 [0.03-0.99] 3/1,467 22/1,472 83% improvement All studies 83% 0.17 [0.03-0.99] 3/1,467 22/1,472 83% improvement 2 paxlovid COVID-19 Randomized Controlled Trials c19early.com/pl Jan 17, 2022 Tau​2 = 0.76, I​2 = 37.8%, p = 0.049 Effect extraction pre-specified Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pfizer (DB RCT) 96% 0.04 [0.00-0.68] 0/1,039 12/1,046 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.025 Early treatment 96% 0.04 [0.00-0.68] 0/1,039 12/1,046 96% improvement All studies 96% 0.04 [0.00-0.68] 0/1,039 12/1,046 96% improvement 1 paxlovid COVID-19 RCT mortality result c19early.com/pl Jan 17, 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.025 Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pfizer (DB RCT) 96% 0.04 [0.00-0.68] death 0/1,039 12/1,046 Improvement, RR [CI] Treatment Control Pfizer (DB RCT) 95% 0.05 [0.00-0.90] death 0/692 9/682 Pfizer (DB RCT) 88% 0.12 [0.06-0.25] hosp. 8/1,039 66/1,046 Pfizer (DB RCT) 89% 0.11 [0.04-0.28] hosp. 5/697 44/682 Pfizer (DB RCT) 70% 0.30 [0.08-1.08] hosp. 3/428 10/426 paxlovid COVID-19 outcomes c19early.com/pl Jan 17, 2022 Favors paxlovid Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. WCH and FLCCC provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit